Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kymera Therapeutics Inc KYMR

Healthcare Biotechnology
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.


NDAQ:KYMR - Post by User

Kymera Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(267)
•••
Post by whytestockson Aug 21, 2024 4:02pm
21 Views
Post# 36190609

Kymera Therapeutics Announces Closing of Upsized $225 Millio

Kymera Therapeutics Announces Closing of Upsized $225 Millio
Just In: $KYMR Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesWATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offer...KYMR - Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities